{
  "timestamp": "2025-12-14T16:35:12.321369",
  "agent": "Patent",
  "molecule": "Atorvastatin",
  "params": {
    "query": "How useful is Atorvastatin for cardiovascular diseases?",
    "args": "('Atorvastatin', 'How useful is Atorvastatin for cardiovascular diseases?')"
  },
  "data": "**Patent Intelligence Report for Atorvastatin**\n\nBased on the provided context, here is a patent intelligence report for Atorvastatin:\n\n---\n\n1.  **Total patent count (approximate)**\n    There are **7 unique patents** identified in the provided context.\n\n2.  **Top assignees**\n    The top assignees based on the context are:\n    *   Lek Pharmaceuticals d.d. (including LEK PHARMACEUTICALS D.D.): 2 patents\n    *   Apotex Pharmachem Inc.: 1 patent\n    *   TEVA PHARMACEUTICAL INDUSTRIES, LTD.: 1 patent\n    *   ARROW INTERNATIONAL LLC: 1 patent\n    *   Zhejiang Neo-Dankong Pharmaceutical Co. Ltd.: 1 patent\n    *   Lifecycle Pharma A/S: 1 patent\n    *   WARNER-LAMBERT COMPANY LLC: 1 patent\n\n3.  **Top inventor countries**\n    The top inventor countries are:\n    *   Canada (CA): 7 inventors\n    *   Slovenia (SI): 4 inventors\n    *   China (CN): 4 inventors\n    *   United States (US): 2 inventors\n\n4.  **Key CPC technology classes**\n    The key CPC technology classes highlight the focus of these patents:\n    *   **C07 / C07D (Organic Chemistry; Heterocyclic compounds)**: This indicates a strong emphasis on the chemical structure, synthesis, and intermediate compounds of Atorvastatin.\n    *   **A61 / A61P (Medical or Veterinary Science; Therapeutic activity of chemical compounds or medicinal preparations)**: This broad class confirms the medical application of Atorvastatin.\n        *   Specifically, **A61P3:06 (Disorders of lipid metabolism)** is a prominent classification across multiple patents, directly addressing Atorvastatin's primary function in managing lipid levels.\n        *   Other significant medical subclasses include **A61P9:00 (Cardiovascular system diseases)**, **A61P7:00 (Blood, circulation)**, **A61P9:10 (Myocardial ischaemia; atherosclerosis)**, and **A61P9:12 (Hypertension)**, underscoring its relevance to cardiovascular health.\n    *   **A61K (Preparations for medical purposes)**: This class appears in patents related to \"Stabilized atorvastatin\" and \"Pharmaceutical compositions of atorvastatin,\" indicating an interest in drug formulation and stability.\n    *   **Y02 (Technologies or applications for mitigation or adaptation against climate change)**: Appears in one patent (Y02P20:55), suggesting an aspect related to sustainable or environmentally conscious manufacturing processes.\n\n5.  **Filing trends over years**\n    Based on the limited data, the patent filing activity for Atorvastatin-related inventions occurred in the following years:\n    *   22005: 1 patent\n    *   22006: 2 patents\n    *   22010: 2 patents\n    *   22013: 2 patents\n    This indicates consistent innovation and patenting efforts in these periods related to Atorvastatin's preparation and formulation.\n\n6.  **Patent landscape summary**\n    The patent landscape for Atorvastatin, as revealed by this context, is primarily focused on **chemical processes for its preparation**, including the creation of intermediates and specific forms like **amorphous calcium salt** and **crystalline sodium atorvastatin**. There is also significant attention paid to **pharmaceutical compositions and stabilization** of the drug.\n\n    **Regarding the utility of Atorvastatin for cardiovascular diseases**, the patent data strongly supports its usefulness. Multiple CPC classifications, specifically under **A61P**, directly link Atorvastatin to therapeutic activities for:\n    *   **Disorders of lipid metabolism (A61P3:06)**, which is crucial for preventing and managing cardiovascular diseases.\n    *   General **cardiovascular system diseases (A61P9:00)**.\n    *   Conditions related to **blood and circulation (A61P7:00)**.\n    *   Specific cardiovascular ailments such as **myocardial ischaemia, atherosclerosis (A61P9:10)**, and **hypertension (A61P9:12)**.\n    The presence of these classifications across several patents indicates that the medical utility of Atorvastatin for treating and managing various cardiovascular-related conditions is a key aspect of the patented inventions."
}